A randomized double-blind trial reported that sodium zirconium cyclosilicate helped more chronic kidney disease patients with heart failure reach target doses of life-prolonging RAAS inhibitors without developing hyperkalemia. The study found a dosing-access benefit tied to improved electrolyte safety. The result targets a persistent clinical bottleneck—balancing guideline-directed RAAS therapy against potassium limits—by potentially widening the population that can tolerate recommended regimens.